Surge. It has announced the signing of a joint research agreement with the University of Tokyo for the purpose of research and development of a new therapeutic drug related to glaucoma surgery. The primary treatment for glaucoma involves administering eye drops, but if eye drops are ineffective depending on the progression, laser treatment or glaucoma surgery may be necessary. Glaucoma surgery not only carries the risk of serious postoperative complications but also may not have sufficient efficacy. The company, along with Tokyo University's Quantitative Life Sciences Research Institute's Special Contract Professor Atsushi Miyajima and Professor Kazuhiro Aihara from the Graduate School of Medicine's Ophthalmology Department, will conduct joint research aiming to develop a groundbreaking new eye drop for glaucoma surgery.